3 Health Care Stocks Dragging The Sector Down

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

One out of the three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading down 53 points (-0.3%) at 16,478 as of Wednesday, Jan. 8, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,242 issues advancing vs. 1,672 declining with 178 unchanged.

The Health Care sector currently sits up 0.9% versus the S&P 500, which is unchanged. A company within the sector that fell today was Humana ( HUM), up 1.4%. Top gainers within the sector include Forest Laboratories ( FRX), up 15.6%, Incyte ( INCY), up 5.8%, Alkermes ( ALKS), up 5.7%, Jazz Pharmaceuticals ( JAZZ), up 5.7% and Endo Health Solutions ( ENDP), up 5.4%.

TheStreet would like to highlight 3 stocks pushing the sector lower today:

3. Sanofi ( SNY) is one of the companies pushing the Health Care sector lower today. As of noon trading, Sanofi is down $0.76 (-1.5%) to $51.15 on heavy volume. Thus far, 3.5 million shares of Sanofi exchanged hands as compared to its average daily volume of 1.2 million shares. The stock has ranged in price between $50.97-$51.31 after having opened the day at $51.28 as compared to the previous trading day's close of $51.91.

Sanofi researches, develops, manufactures, and markets healthcare products worldwide. The company operates through Pharmaceuticals, Human Vaccines, and Animal Health segments. Sanofi has a market cap of $138.5 billion and is part of the drugs industry. The company has a P/E ratio of 27.9, above the S&P 500 P/E ratio of 17.7. Shares are down 3.2% year to date as of the close of trading on Tuesday. Currently there are 2 analysts that rate Sanofi a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Sanofi as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Sanofi Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Biotech Mailbag: Buy Dip in T2 Biosystems?

FDA Official Calls for Ending Codeine Use in Kids Cough Products

Big Drug Makers Could Face More Pressure on Codeine Remedies for Kids

Sanofi Has Good Potential Upside

European Pharma Companies Slip on MS Pricing Probe